Barclays’s Evolent Health EVH Stock Holding History

Barclays’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100	Closed	-$3K	–	7040
2018 Q3	$3K	Buy	+100	New	+$2.38K	﹤0.01%	6881

Other funds holding EVH

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $147M AUM 17% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Rock Point Advisors Burlington, Vermont $402M AUM 17.12% 1-Year Est. Return

Barclays's EVH Position: Q3 2026 in Review

Barclays increased its Evolent Health (EVH) stake by 40% in Q3 2026, buying an estimated $128K and bringing the position to 100,253 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #3656.

Barclays first reported a position in EVH in Q2 2016 and has held it in 42 quarters since. The position peaked at $12.7M in Q2 2025. 129 funds tracked by Wall St. Rank hold EVH as of Q3 2026.

Barclays held 100,253 shares of Evolent Health worth $350K as of Q3 2026.
Barclays bought 28,765 Evolent Health shares in Q3 2026, an estimated $128K.
Evolent Health made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3656 holding.
Barclays first reported a position in Evolent Health in Q2 2016 and has held it in 42 quarters since.
Barclays's Evolent Health position peaked at $12.7M in Q2 2025.
129 funds tracked by Wall St. Rank held Evolent Health as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.